Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Prostate Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Rana R McKay, including the following topics.

Role of Hormonal Therapy in Prostate Cancer (PC) Management — Dr McKay (0:00)
Evidence-Based Use of Other Therapeutic Approaches — Dr Antonarakis (35:15)

CME information and select publications

Urothelial Bladder Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Matthew D Galsky and Dr Jonathan E Rosenberg, including the following topics.

Introduction (0:00)
Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky (5:45)
Metastatic UBC — Dr Rosenberg (31:51)

CME information and select publications

Renal Cell Carcinoma | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Eric Jonasch and DR Brian Rini, including the following topics.

Introduction (0:00)
Current Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Rini (5:11)
Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr Jonasch (38:52)

CME information and select publications

Metastatic HER2-Positive and Triple-Negative Breast Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Erika Hamilton, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics.

HER2-Positive Metastatic Breast Cancer — Dr Hamilton (0:00)
Metastatic Triple-Negative Breast Cancer — Dr Rugo (29:06)
SABCS® 2023 Review — Dr Kaklamani (45:20)

CME information and select publications

Localized Breast Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Virginia Kaklamani, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics.

Introduction (0:00)
Localized HER2-Positive and Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:52)
SABCS® 2023 Review — Dr Kaklamani (31:48)
Localized ER-Positive Breast Cancer — Dr Kalinsky (38:10)

CME information and select publications

Gynecologic Cancers | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Bradley J Monk and Dr David M O'Malley, including the following topics.

Introduction (0:00)
Ovarian Cancer; Role of HER2-Directed Therapy in Gynecologic Cancers — Dr O'Malley (4:36)
Endometrial Cancer and Cervical Cancer — Dr Monk (27:59)

CME information and select publications

Hodgkin and Non-Hodgkin Lymphoma | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics.

Introduction (0:00)
Follicular Lymphoma (FL) — Dr Zelenetz (2:29)
Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04)
Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36)
Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53)

CME information and select publications

ER-Positive Metastatic Breast Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Joyce O'Shaughnessy and Dr Hope S Rugo, including the following topics.

Introduction (0:00)
Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr O'Shaughnessy (5:46)
Role of Oral Selective Estrogen Receptor Degraders (SERDs) in the Treatment of ER-Positive mBC — Dr Hamilton (43:06)
Novel Strategies Targeting the PI3K/AKT/mTOR Signaling Pathway in ER-Positive mBC — Dr Kalinsky (57:22)
Current and Future Role of Antibody-Drug Conjugates (ADCs) in the Management of ER-Positive mBC — Dr Rugo (1:17:49)
Breast Cancer in the Real World (1:40:29)

CME information and select publications

Ovarian Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Ovarian Cancer Apr 17, 2024

Show notes

Featuring perspectives from Dr Joyce F Liu, Dr Mansoor Raza Mirza and Dr David M O'Malley, moderated by Dr Kathleen N Moore, including the following topics:

Introduction (0:00)
Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:06)
Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O'Malley (25:12)
Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore (48:23)
Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza (1:06:59)

CME information and select publications

Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition (Companion Faculty Lecture) Apr 16, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics:

Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00)
Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56)
Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52)
Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11)
Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56)
Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39)

CME information and select publications